Also in this playlist...
This transcript is automatically generated
Have you seen shares of Dendreon ticker symbol DND and they are skyrocketing today as the small Biotech company announced.
I stress could have a blockbuster cancer drug on its hands it's called for revenge the name of the drug and it's a vaccine.
For late stage prostate cancer it has shown in -- study that it actually improves survival for patients.
In late stage prostate cancer joining us now with -- -- managing director with Lazard Capital Markets to.
Sort of pick us apart and tell us why this news appears to be so good for small stock.
Well most important thing is they hit a survival one point and that's the most important -- most difficult test for any small company and as.
And the emerging drug to be able -- that they should this morning and this was a group.
A study of about 500 patients who we've gotten this.
This experimental vaccine if you well that's right.
It was hormonal factor prostate cancer and what that means and not common terms is it's people that had the initial diagnosis of prostate cancer and they failed their first level of therapy hormone therapy and and then they go on pro events and they test the pro event vs placebo.
-- and showed a survival benefit but we don't know the magnitude happen.
-- -- let me explain how this drug sort of works everyday it basically what they're doing it as I understand it is tiny fragments of the patient's tumor.
Are extracted are then sent to a lab where specific proteins that are linked to the cancer are -- incorporated into a vaccine.
Then you inject the vaccine -- -- and then the body's immune system attacks the cancer cells so it appeared to work.
We called immunotherapy.
And there hasn't ever been a case where an immunotherapy like this.
It's a traditional vaccine that's a vaccine that boosts your own responses as opposed to.
Normal like flu vaccine or something like that's what's different in that regard.
And -- so many of the other ones of failed -- a lot of skepticism.
About the potential for this and even in this drug itself we have positive survival benefit that we need to see more of the details and we'll see that in two weeks and -- We aka the company still has to get a filing there's a lot to be done let's talk about the cost if it were to come to market prohibitive now -- -- potentially much.
We're estimating about 50000 dollars a year could be more and it's also very.
Expensive drug in -- cumbersome drug to potentially give given the fact -- have to take a patient takes sells out.
Modify those cells and delivering back to the patients that costs a lot of money.
And -- relative basis drugs like this or anybody's that are not quite as difficult to produce cost 5200000.
We -- this study was going on why is it that the analyst community and and perhaps you were different I don't know I'd let you know didn't peg.
That this would be a screening by at some point.
Right we were very skeptical I mean what -- we said as their fifth there was a 5050 chance mainly because there is.
Other evidence -- earlier trials that this drug worked on the other hand we have a whole.
List of other drugs that have tried this approach that didn't I think fifteen years' worth of cancer immunotherapy is did not work they think that's right that's right.
And so there's a whole reason.
To be skeptical whole list of reasons to be skeptical on this type of approach and that's what -- that mystery to you let's say it comes to market from my father was a urologist and hit it dealt very specifically with prostate cancer -- he was always getting calls from pharmaceutical companies and try -- new drug -- mind.
Do physicians warm up.
To these types of therapies quickly or does it takes some time to figure out yet this is the one I'm gonna try my patient well becomes difficult you know it we have -- -- the detailed data doctors are always asking for all the details and went up drug launches some doctors immediately.
Grass didn't start to use it other doctors the fence sitters we column wait for other doctors use -- other patients and see how they react to it's going to take time.
And even before you get there you have the regulatory hurdles and that involves -- if you file does this mean that Dendreon could become a much bigger pharmaceutical company at some point due -- one drug charge shortly many other companies have done and be on the back of one drug.
But there are many challenges that lie ahead I mean certainly was a big.
You need regulatory approval and you -- marketing plan to call this advice hold what are you looking it'll hold rating on -- right now because despite the attractive data it is is that a market cap right now it is not caught on -- to some other companies that have profits than drugs approved that are on the market right now.
-- -- of Lazard Capital Markets that to have your perspective thank you that's what we're back again you're welcome any time let me get.
Filter by section